When it comes to the treatment of patients with nonmetastatic castration-resistant prostate cancer (M0CRPC), 3 pivotal trials—SPARTAN, PROSPER, and most recently, ARAMIS—have demonstrated the safety and efficacy of second-generation targeted antiandrogens, said Richard (Rick) JaeBong Lee, MD, PhD.
While Lynch syndrome may be more common than originally thought, research continues to move forward to improve the outcomes of this patient population.
The FDA approved ramucirumab (Cyramza) as a single-agent treatment for patients with hepatocellular carcinoma (HCC) with an alpha fetoprotein (AFP) of ≥ 400 ng/mL and have been previously treated with sorafenib (Nexavar).
Nivolumab plus radiation did not improve overall survival compared to temololomide in patients with newly diagnosed glioblastoma.
Chemotherapy-induced peripheral neuropathy affects the daily activities of patients and survivors, but nurses can be key players in helping patients who develop the condition.
The Food and Drug Administration granted leronlimab a fast track designation for the treatment of patients with metastatic triple-negative breast cancer.
Healthcare providers of all disciplines should work together to educate individuals about the symptoms of colorectal cancer.
We asked patients, survivors, and caregivers to give their oncology nurses a shout out. Here's what they had to say.
Generous Donor to Match Every Donation up to $100,000 to the Tyler Trent Fund
Funds Raised to Support Cancer Research in Virginia, Nationwide
The FDA approved ado-trastuzumab emtansine for the treatment of HER2-positive early breast cancer, after it showed a 50% decrease of disease or death compared with trastuzumab.
The FDA has approved a supplemental new drug application (sNDA) for ivosidenib (Tibsovo) as a single agent for the first-line treatment of adult patients with IDH1-mutant acute myeloid leukemia (AML), as detected by an FDA-approved test, who are ≥75 years old or are ineligible to receive intensive chemotherapy.
The HPV vaccine is commonly associated with preventing cervical cancer, but it plays a major role in oral cancers, too.
Here are the top 5 Oncology Nursing News stories for April 2019.
The FDA has granted a priority review designation to a new drug application (NDA) for darolutamide for use as a treatment for patients with nonmetastatic castration-resistant prostate cancer (CRPC).
Despite stating that they tell their loved ones everything, there are some details that patients with gynecologic cancer tend to leave out.
The use of oral contraceptives not only decreases a woman’s risk of developing ovarian cancer, but can also decrease the risk of dying from the disease, too, according to recent research.
In the middle of the night in June 2015, David Yoskowitz’s experience woke him with a groundbreaking idea: a cold mouthpiece that would combat chemotherapy-associated mouth sores.
Nurses play a key role in the multidisciplinary approach that is needed to care for patients with neuroendocrine tumors (NETs).
Certain patients with colorectal cancer may see a cure thanks to new, tailored approaches.
Monoclonal antibodies and CAR-T cell therapy is changing the way that patients with myeloma are treated.
Although Minority Health Awareness Month is drawing to an end, the fight for equity in healthcare isn’t over.
Take a look at what's inside our April 2019 issue.
The FDA has approved pembrolizumab (Keytruda) in combination with axitinib (Inlyta) for the frontline treatment of patients with advanced renal cell carcinoma (RCC).
There are special concerns for oncology nurses when treating LGBTQ patients, according to a panel of experts that presented at the 2019 Oncology Nursing Society (ONS) Annual Congress in Anaheim, CA.
Dr. Jinsil Seong, Professor at Yonsei University Medical College, is honored for her ground-breaking work in primary liver cancer.
The FDA granted an accelerated approval for erdafitinib to treat patients with metastatic or locally advanced bladder cancer that harbors certain genetic mutations.
The FDA has expanded the approval for pembrolizumab (Keytruda) monotherapy for the frontline treatment of patients with stage III non–small cell lung cancer (NSCLC), who are ineligible for surgery or definitive chemoradiation, or metastatic NSCLC, with a PD-L1 expression (tumor proportion score [TPS]) level of ≥1% and do not harbor EGFR or ALK aberrations.
